Stock Scorecard



Stock Summary for Geron Corp (GERN) - $1.40 as of 9/4/2025 1:28:57 PM EST

Total Score

6 out of 30

Safety Score

32 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GERN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GERN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GERN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GERN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GERN (32 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for GERN

SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors - Genmab ( NASDAQ:GMAB ) , Geron ( NASDAQ:GERN ) 8/19/2025 12:00:00 PM
GERON ( GERN ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Geron ( NASDAQ:GERN ) 8/13/2025 11:52:00 PM
Geron ( GERN ) Q2 Revenue Jumps 5,477% 8/6/2025 2:04:00 PM
Geron ( GERN ) Reports Q2 Loss, Tops Revenue Estimates 8/6/2025 12:15:00 PM
Incyte ( INCY ) Surpasses Q2 Earnings and Revenue Estimates 7/29/2025 12:20:00 PM
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound - Everus Construction Group ( NYSE:ECG ) , Geron ( NASDAQ:GERN ) 7/18/2025 1:20:00 PM
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Geron ( NASDAQ:GERN ) 5/16/2025 1:00:00 AM
The Gross Law Firm Notifies Shareholders of Geron Corporation ( GERN ) of a Class Action Lawsuit and an Upcoming Deadline - Geron ( NASDAQ:GERN ) 5/12/2025 5:12:00 PM
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN - Geron ( NASDAQ:GERN ) 5/11/2025 12:17:00 PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERN 5/11/2025 11:13:00 AM

Financial Details for GERN

Company Overview

Ticker GERN
Company Name Geron Corp
Country USA
Description Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/6/2025

Stock Price History

Last Day Price 1.40
Price 4 Years Ago 1.22
Last Day Price Updated 9/4/2025 1:28:57 PM EST
Last Day Volume 9,027,322
Average Daily Volume 10,264,658
52-Week High 4.83
52-Week Low 1.09
Last Price to 52 Week Low 28.44%

Valuation Measures

Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE -11.61
Free Cash Flow Ratio 11.67
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 7.87
Total Cash Per Share 0.12
Book Value Per Share Most Recent Quarter 0.41
Price to Book Ratio 3.61
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 5.70
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 638,017,000
Market Capitalization 893,223,800
Institutional Ownership 81.97%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 7.75%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 5.19%
Reported EPS 12 Trailing Months -0.13
Reported EPS Past Year -0.05
Reported EPS Prior Year -0.27
Net Income Twelve Trailing Months -88,009,000
Net Income Past Year -174,572,000
Net Income Prior Year -184,127,000
Quarterly Revenue Growth YOY 5,460.00%
5-Year Revenue Growth 178.45%
Operating Margin Twelve Trailing Months -25.40%

Balance Sheet

Total Cash Most Recent Quarter 77,734,000
Total Cash Past Year 79,016,000
Total Cash Prior Year 70,023,000
Net Cash Position Most Recent Quarter -41,257,000
Net Cash Position Past Year -39,460,000
Long Term Debt Past Year 118,476,000
Long Term Debt Prior Year 35,051,000
Total Debt Most Recent Quarter 118,991,000
Equity to Debt Ratio Past Year 0.70
Equity to Debt Ratio Most Recent Quarter 0.69
Total Stockholder Equity Past Year 280,320,000
Total Stockholder Equity Prior Year 247,949,000
Total Stockholder Equity Most Recent Quarter 259,531,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -178,560,000
Free Cash Flow Per Share Twelve Trailing Months -0.28
Free Cash Flow Past Year -219,298,000
Free Cash Flow Prior Year -168,573,000

Options

Put/Call Ratio 0.51
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.03
MACD Signal 0.03
20-Day Bollinger Lower Band 1.14
20-Day Bollinger Middle Band 1.38
20-Day Bollinger Upper Band 1.62
Beta 0.73
RSI 55.40
50-Day SMA 2.53
150-Day SMA 2.78
200-Day SMA 2.48

System

Modified 9/4/2025 12:31:07 AM EST